Delivery Order SPE2DB24D1034-SPE2DB25FWER4
- Not listed
- The Defense Logistics Agency awarded a $2,499.84 delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin infusion pods. The contract, which became effective on September 10, 2025, with completion targeted for September 11, 2025, utilizes firm fixed pricing with no set-aside designation and was competitively awarded. Performance will be executed from AmerisourceBergen's corporate offices in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order valued at $1,138.73 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin delivery pods. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 31, 2025, and represents a child contract under AmerisourceBergen's broader pharmaceutical supply agreements with DLA. The products will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on June 27, 2025, for the supply of OmniPod 5 Dexcom G7 Generation 5 insulin infusion pods. The contract is valued at $9,577.85 under a firm fixed-price arrangement with an ultimate completion date of June 30, 2025. This delivery order is not set-aside and represents a competitive award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- This delivery order, valued at $1,629.76, was awarded to AmerisourceBergen Drug Corp on August 21, 2025, by the Defense Logistics Agency (DLA) for the supply of OmniPod 5 Dexcom G7 Generation 5 insulin delivery pods. The contract is a firm fixed-price delivery order with an ultimate completion date of August 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was not designated as a set-aside contract and represents a...
- The Defense Logistics Agency awarded a delivery order valued at $2,793.30 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Gen 5 insulin infusion pods. This competitively awarded, non-set-aside contract carries a firm fixed price structure with an ultimate completion date of August 4, 2025. The order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, supporting federal medical supply chain requirements. This delivery order represents a child...
- This delivery order, valued at $1,018.60, was awarded by the Defense Logistics Agency to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of OmniPod 5 Dexcom G7 Generation 5 insulin infusion pods. The contract utilizes a firm fixed price structure with no set-aside designation, indicating competitive award. Performance will be executed from the contractor's location in Conshohocken, Pennsylvania, with an ultimate completion date of August 11, 2025. This delivery order is a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for OmniPod 5 Dexcom G7 Generation 5 insulin infusion pods valued at $1,222.32. This is a firm fixed-price delivery order with no set-aside designation, utilizing competitive procurement procedures. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 vehicle running through December...
- The Defense Logistics Agency awarded a delivery order valued at $1,193.52 to AmerisourceBergen Drug Corp on June 3, 2025, for OmniPod 5 Dexcom G7 Generation 5 insulin delivery pods. This competitive award, with no set-aside designation, was issued under firm fixed pricing and is scheduled for completion by June 4, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract, this delivery order is supported by...
- The Defense Logistics Agency (DLA) awarded a $17,144.30 delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin delivery pods. This competitively awarded, firm fixed-price contract is scheduled for completion by July 31, 2025, with performance taking place at the contractor's Conshohocken, Pennsylvania facility. The delivery order carries no set-aside designation and represents a continuation of the company's extensive medical supply support to federal...
- The Defense Logistics Agency awarded a $6,666.30 delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin infusion pods. The contract, issued on September 23, 2025, with an ultimate completion date of September 24, 2025, represents a firm fixed-price delivery under a competitively awarded, non-set-aside arrangement. Performance will take place at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is a child contract issued against...
- SPE2DB24D1034Indefinite Delivery Contract
- SPE2DB24D1034-SPE2DB25FWER4Delivery Order
This delivery order, valued at $3,666.96, was awarded on July 28, 2025, to AmerisourceBergen Drug Corp for the supply of Omnipod 5 Dexcom G7 Generation 5 insulin delivery pods. The contract is a firm fixed price delivery order issued by the Defense Logistics Agency (DLA), a component of the U.S. Department of Defense responsible for supplying medical and pharmaceutical products to military healthcare systems. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. No set-aside designation was applied to this award, indicating it was competitively procured. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a ceiling value of $999,999,999.00 and extends through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen's demonstrated capability in federal medical procurement, combined with its extensive portfolio of specialty medications and medical devices, positions the company as a critical vendor for delivering specialized healthcare commodities such as insulin delivery systems to Defense Health Agency and other federal healthcare beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.7k | 7/28/25 |